Our laboratory is involved in two separate projects designed to identify, characterize and clone tumor susceptibility/resistance genes in mouse B cell (plasmacytoma) and skin (squamous cell carcinoma) cancer model systems. In the mouse plasmacytoma system, we have documented that at least 4 genes are involved in determining the susceptibility patterns seen in BALB/cAn mice. Three of these genes, Pctr1-3, reside in the mid and distal portions of mouse Chr4. The Pctr1 region shares linkage homology with human 9p21 and 1p31. The Pctr2 and 3 regions in the mouse also share linkage homology with human Chr 1p, abnormalities of which have been documented in a variety of human cancers, including breast, neuroblastoma, melanoma, Burkitts lymphoma and multiple myeloma.The cyclin dependent kinase inhibitor Cdkn2a (p16, p19) was mapped within the Pctr1 critical region. Two sequence variants were identified between susceptible and resistant mice. Site-directed mutagenesis experiments of Cdkn2a were performed to construct GST- fusion proteins containing the allelic variants associated with the susceptible strain. These proteins did not inhibit phosphorylation of RB in kinase assays and did not bind to CDK4-CyclinD2 complexes. Furthermore, when the DBA/2 p16 variant was transfected into two separate plasmacytoma cell lines, many cells were blocked at G1. In contrast, cells transfected with the BALB/c variants continue to cycle. Plasmacytomagenesis is accelerated in knock-out mice. These data strongly implicate the Cdkn2a locus as the Pctr1 tumor susceptibility gene.In the Pctr2 region, a series of tumor induction studies coupled with allelotypic analyses of a series of recombinant congenic strains have narrowed the genetic interval harboring the susceptibility/resistance gene to 1-2 cM. The Pctr2 locus was found to act in a codominant fashion in studies of F1 hybrids between resistant and susceptible congenic strains of mice. Phenotypic effects of the Pctr2 locus were evident in delaying the onset of tumorigenesis and reducing tumor incidences. Efforts have been concentrated on developing a physical map of the region. Sample sequencing and EST matches have identified 4 new genes in the Pctr2 intrerval. These genes are being evaluated as candidates for the Pctr2 locus.In the skin cancer model, we have examined genetic markers distributed across the genome in progeny from a cross between resistant and susceptible mice to test for associations of susceptibility/resistance patterns with marker alleles. We have found 1 major gene on Chr 5 and evidence for other genes on Chrs 9,11 and 12, which are linked to tumor susceptibility. We have created congenic strains to further delineate the region of Chr 5 involved. - Animal models, B lymphocytes, Burkitt's lymphoma, Cancer genetics, gene mapping, Genetic Susceptibility, myeloma, - Neither Human Subjects nor Human Tissues
| Zhang, Shuling; Qian, Xiaolan; Redman, Chanelle et al. (2003) p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene 22:2285-95 |
| Bliskovsky, Valery; Ramsay, Edward S; Scott, John et al. (2003) Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci U S A 100:14982-7 |
